Polo-like kinase 1 Decrease During Induction Therapy Could Indicate Good Treatment Response, Favorable Risk...

Area of Science:

• Oncology
• Molecular Biology
• Pediatric Hematology

Background:

• Polo-like kinase 1 (PLK1) is implicated in cell cycle regulation and apoptosis, crucial processes in acute lymphoblastic leukemia (ALL) progression.
• Understanding PLK1's role in pediatric ALL is vital for assessing treatment efficacy and patient prognosis.

Purpose of the Study:

• To investigate the expression levels of PLK1 in pediatric ALL patients.
• To determine the association between PLK1 levels, response to induction therapy, and survival outcomes in pediatric ALL.

Main Methods:

• Quantitative reverse transcription-polymerase chain reaction (RT-qPCR) was used to measure PLK1 expression in bone marrow samples.
• Samples were collected from 90 pediatric ALL patients at baseline and day 15 of induction therapy, along with 20 healthy controls.

Main Results:

• PLK1 expression was significantly higher in pediatric ALL patients compared to controls.
• PLK1 levels decreased from baseline to day 15 of induction therapy in ALL patients.
• Lower baseline PLK1 and a decline of ≥25% after induction therapy were associated with favorable prednisone response, better bone marrow response, improved event-free survival (EFS), and overall survival (OS).

Conclusions:

• PLK1 reduction post-induction therapy signifies a positive treatment response in pediatric ALL.
• PLK1 levels and their decline serve as a valuable biomarker for predicting treatment response and survival in pediatric ALL patients.